Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-18T23:02:23.518Z Has data issue: false hasContentIssue false

11 - Liver, gallbladder and biliary tract

Published online by Cambridge University Press:  23 December 2009

Somnath Mukherjee
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Tom Crosby
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Hospital, Cardiff
Get access

Summary

Introduction

Primary liver cancer is one of the most common cancers worldwide, and it predominantly affects people in developing countries. It is often associated with chronic liver infections and it is more common in males. Patients usually present with advanced disease and treatment options are influenced, and often limited, by co-morbidities, especially poor function of the rest of the liver.

Tumours of the gallbladder and biliary tract are relatively rare. Patients often present late with symptoms of biliary obstruction which, together with cholangitis, is a common cause of morbidity and death and is the main target for palliative therapies. Gallbladder and biliary tract tumours are moderately chemosensitive. Cytological or histological confirmation of disease is often difficult, and specialist multidisciplinary teams of expert radiologists and pathologists should be involved in the diagnosis and staging. Radical surgery should only be carried out by tertiary surgical teams, and patients should be managed, whenever possible, within clinical trials.

Tumours of the liver

The types of tumour that affect the liver are shown in Table 11.1.

Anatomy of the liver

The liver is divided into right and left lobes by the falciform ligament, but more importantly, in terms of surgical resection, a segmental division can be made and seen with imaging based on the relationship to the hepatic and portal veins. There are four segments in both the left and the right liver.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anderson, C. D., Rice, M., Pinson, C. W.et al. (2004). Fluorodeoxyglucose positron emission tomography imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J. Gastrointest. Surg., 8, 90–7.CrossRefGoogle ScholarPubMed
Bismuth, H. and Corlette, M. B. (1975). Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg. Gynecol. Obstet., 140, 170–8.Google ScholarPubMed
Bismuth, H., Majno, P. E. and Adam, R. (1999). Liver transplantation for hepatocellular carcinoma. Semin. Liver Dis., 19, 311–22.CrossRefGoogle ScholarPubMed
Chamberlain, R. S. and Blumgart, L. H. (2000). Hilar cholangiocarcinoma: a review and commentary. Ann. Surg. Oncol., 7, 55–66.CrossRefGoogle ScholarPubMed
Chen, J. S., Lin, Y. C., Jan, Y. Y.et al. (2001). Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. Anticancer Drugs, 12, 339–43.CrossRefGoogle ScholarPubMed
Cho, J. Y., Paik, Y. H., Chang, Y. S.et al. (2005). Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer, 104, 2753–8.CrossRefGoogle ScholarPubMed
Choi, C. W., Choi, I. K., Seo, J. H.et al. (2000). Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am. J. Clin. Oncol., 23, 425–8.CrossRefGoogle ScholarPubMed
Fong, Y., Sun, R. L., Jarnagin, W.et al. (1999). An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann. Surg., 229, 790–800.CrossRefGoogle Scholar
Kim, T. W., Chang, H. M., Kang, H. J.et al. (2003). Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann. Oncol, 14, 1115–20.CrossRefGoogle ScholarPubMed
Kornek, G. V., Schuell, B., Laengle, F.et al. (2004). Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann. Oncol., 15, 478–83.CrossRefGoogle ScholarPubMed
Lau, W. Y., Leung, T. W., Ho, S. K.et al. (1999). Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet, 353, 797–801.CrossRefGoogle ScholarPubMed
Lau, W. Y., Leung, T. W., Ho, S.et al. (1994). Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br. J. Cancer, 70, 994–9.CrossRefGoogle ScholarPubMed
Lau, W. Y., Leung, T. W., Lai, B. S.et al. (2001). Pre-operative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann. Surg., 233, 236–41.CrossRefGoogle Scholar
Leung, T. W. T., Patt, Y. Z., Lau, W. Y.et al. (1999). Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res., 5, 1676–81.Google ScholarPubMed
Llovet, J. M., Fuster, J. and Bruix, J. (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology, 30, 1434–40.CrossRefGoogle ScholarPubMed
Llovet, J. M., Burroughs, A. and Bruix, J. (2003). Hepatocellular carcinoma. Lancet, 362, 1907–17.CrossRefGoogle ScholarPubMed
Lozano, R. D., Patt, Y. Z., Hassan, M. M.et al. (2000). Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer). Proc. Am. Soc. Clin. Oncol., 19, Abstr. 1025.Google Scholar
Maindrault-Goebel, F., Selle, F., Rosmorduc, O.et al. (2003). A phase II study of gemcitabine and oxaliplatin (GEMOX) in advanced biliary adenocarcinoma (ABA). Final results. Proc. Am. Soc. Clin. Oncol., 22, Abstr. 1178.Google Scholar
Mazzaferro, V., Regalia, E., Doci, R.et al. (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med., 334, 693–9.CrossRefGoogle ScholarPubMed
Mitry, E., Custem, E., Laethem, J.et al. (2002). A randomised phase II trial of weekly high-dose 5FU (HD-FU) with and without folinic acid (folinic acid) and cisplatin (P) in patients (pts) with advanced biliary tract carcinoma: the European Organisation for Research and Treatment of Cancer 40955 trial. Proc. Am. Soc. Clin. Oncol., 21, Abstr. 696.Google Scholar
Muto, Y., Moriwaki, H., Ninomiya, M.et al. (1996). Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N. Engl. J. Med., 334, 1561–7.CrossRefGoogle ScholarPubMed
Nakagohri, T., Asano, T., Kinoshita, H.et al. (2003). Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J. Surg, 27, 289–93.CrossRefGoogle ScholarPubMed
O'Reilly, E. M., Stuart, K. E., Sanz-Altamira, P. M.et al. (2001). A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer, 91, 101–5.3.0.CO;2-K>CrossRefGoogle ScholarPubMed
Ortner, M. (2001). Photodynamic therapy for cholangiocarcinoma. J. Hepatobil. Pancreat. Surg., 8, 137–9.CrossRefGoogle ScholarPubMed
Philip, P. A., Mahoney, M., Thomas, J.et al. (2004). Phase II trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. J. Clin. Oncol., 2004 American Society of Clinical Oncology Meeting Proceedings (Post-Meeting Edition), 22 (no. 14S July 15 Suppl.), 4025.Google Scholar
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L.et al. (1973). Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg., 60, 646–9.CrossRefGoogle ScholarPubMed
Roayaie, S., Frischer, J. S., Emre, S. H.et al. (2002). Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimetres. Ann. Surg., 235, 533–9.CrossRefGoogle Scholar
Schwartz, J. D., Schwartz, M. V., Goldman, J.et al. (2004). Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein. J. Clin. Oncol., 2004 American Society of Clinical Oncology Meeting Proceedings (Post-Meeting Edition), 22 (14S July 15 Suppl.), 4088.Google Scholar
Seong, J., Keum, K. C., Han, K. H.et al. (1999). Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 43, 393–7.CrossRefGoogle ScholarPubMed
Takada, T., Amano, H., Yasuda, H.et al. (2002). Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer, 95, 1685–95.Google ScholarPubMed
International Union Against Cancer. (2002). tumour nodes metastases Classification of Malignant Tumours, ed. Sobin, L. H. and Ch. Wittekind, , 6th edn. New York: Wiley-Liss, pp. 81–3.Google Scholar
Yang, T. S., Lin, Y. C., Chen, J. S.et al. (2000). Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 89, 750–6.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Yeo, W., Mok, T. S., Zee, B.et al. (2005). A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (cisplatin, interferon, doxorubicin, 5-FU) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst., 97, 1532–8.CrossRefGoogle ScholarPubMed
Yoshida, H., Tateishi, R., Arakawa, Y.et al. (2004). Benefits of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut, 53, 425–30.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×